Indication
Hypertrophic Cardiomyopathy
17 clinical trials
17 products
1 drug
Clinical trial
A Long-Term Safety Extension Study of Mavacamten (MYK-461) in Adults With Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)Status: Active (not recruiting), Estimated PCD: 2030-03-15
Product
mavacamtenClinical trial
A Multi-Center, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Symptomatic Hypertrophic CardiomyopathyStatus: Completed, Estimated PCD: 2023-02-28
Product
CK-3773274Product
CK-3773274 PlaceboClinical trial
An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)Status: Completed, Estimated PCD: 2023-11-09
Product
PlaceboClinical trial
A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment of Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)Status: , Estimated PCD: 2026-03-01
Clinical trial
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of HS-10511 in Healthy SubjectsStatus: Not yet recruiting, Estimated PCD: 2024-06-30
Product
HS-10511Clinical trial
First-in-Human, Open-Label, Safety, Tolerability, Dose-Finding, Pharmacodynamic and Cardiac Transgene Expression Study of TN-201, a Recombinant Adenoassociated Virus Serotype 9 (AAV9) Containing Myosin Binding Protein C Transgene, in Adults With MYBPC3 Mutation-Associated Hypertrophic Cardiomyopathy (HCM)Status: Recruiting, Estimated PCD: 2025-12-01
Product
TN-201Clinical trial
mavaCamten ObservationaL evIdence Global cOnsortium in HCM (COLLIGO-HCM)Status: Active (not recruiting), Estimated PCD: 2025-03-01
Product
MavacamtenProduct
Hypertrophic CardiomyopathyClinical trial
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic CardiomyopathyStatus: Completed, Estimated PCD: 2023-09-18
Product
IMB-1018972Clinical trial
An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of EDG-7500 in Adults With Obstructive Hypertrophic CardiomyopathyStatus: Recruiting, Estimated PCD: 2025-03-01
Product
EDG-7500Clinical trial
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic CardiomyopathyStatus: Not yet recruiting, Estimated PCD: 2028-12-01
Product
AficamtenClinical trial
Mavacamten Pregnancy Surveillance ProgramStatus: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic CardiomyopathyStatus: Not yet recruiting, Estimated PCD: 2027-04-01
Product
SotagliflozinClinical trial
Sodium-dependent Glucose Transporters 2 Inhibitor in Nonobstructive Hypertrophic Cardiomyoapthy Patients With Heart Failure With Preserved Ejection Fraction: a Prospective, Multi-center,Open-lable,Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2024-08-01
Product
EmpagliflozinClinical trial
A Randomised, Double-blind, Placebo-controlled, Phase 2 Evaluation of the Efficacy and Mechanism of Trientine in Patients With Hypertrophic CardiomyopathyStatus: Active (not recruiting), Estimated PCD: 2024-04-30
Product
TrientineDrug
VarlilumabClinical trial
The Use of Empagliflozin in Patients With Hypertrophic CardiomyopathyStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic CardiomyopathyStatus: Completed, Estimated PCD: 2023-02-23
Product
MetoprololClinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of SOtaglifloziN in symptomATic Obstructive And Non-obstructive Hypertrophic CardioMyopathy (SONATA-HCM)Status: Recruiting, Estimated PCD: 2026-07-01